Incyte (INCY): Revisiting Valuation After a Strong Year-to-Date Share Price Rally [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
See our latest analysis for Incyte. That move has been driven largely by renewed confidence in Incyte's pipeline and steady revenue growth, with a robust year to date share price return helping to lift its one year total shareholder return and signal building momentum rather than a one off spike. If this kind of run has you rethinking your healthcare exposure, it could be a good moment to scout other promising names through healthcare stocks With shares now hovering just below Wall Street's price targets but still trading at a hefty intrinsic discount, the key question is whether Incyte is attractive at current levels or if the market is already pricing in its future growth. With Incyte last closing at $97.63 against a narrative fair value near $99.62, the story leans toward modest upside rather than deep value. The analysts have a consensus price target of $80.727 for Incyte based on their expectations of its future earnings growth, profit margins and other risk factors. H
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte to Present at Upcoming Investor ConferenceBusiness Wire
- UCB's Bimzelx Continues to Shift Biologic Treatment Patterns in Hidradenitis Suppurativa as Demand for Innovation Grows, According to Spherix Global Insights [Yahoo! Finance]Yahoo! Finance
- Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular LymphomaBusiness Wire
- Is Incyte Stock Outperforming the Nasdaq? [Yahoo! Finance]Yahoo! Finance
- CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China [Yahoo! Finance]Yahoo! Finance
INCY
Earnings
- 10/28/25 - Beat
INCY
Sec Filings
- 12/18/25 - Form 144
- 12/18/25 - Form 4
- 12/17/25 - Form 144
- INCY's page on the SEC website